Catalog No.S1293 Synonyms: FRC-8653
Molecular Weight(MW): 492.52
Cilnidipine is a unique L-type and N-type calcium channel blocker, used for high blood pressure treatment.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
|Description||Cilnidipine is a unique L-type and N-type calcium channel blocker, used for high blood pressure treatment.|
Cilnidipine (10 mM) suppresses the elevation of the ratio induced by 40 mM KCl, and this suppression is effectively inhibited after the treatment with omega-conotoxin GVIA.
|In vivo||Cilnidipine reduces Ca(2+) influx via N-type Ca(2+) channels after NMDA receptors activation and then protects neurons against ischemia-reperfusion injury in the rat retina in vivo.  Cilnidipine significantly prevents the increase in desmin staining and restores the glomerular podocin and nephrin expression compared with amlodipine in spontaneously hypertensive rat/ND mcr-cp (SHR/ND). Cilnidipine also prevents the increase in renal angiotensin II content, the expression and membrane translocation of NADPH oxidase subunits and dihydroethidium staining in SHR/ND.  Cilnidipine (30 mg/kg/d as food admix) treatment suppresses the increase in systolic blood pressure in Dahl salt-sensitive rats. Cilnidipine inhibits the increase in blood urea nitrogen and decrease in creatinine clearance as well as progression of glomerular sclerosis. Cilnidipine reduces plasma norepinephrine level and plasma rennin activity compared with vehicle-treated Dahl S rats.  Cilnidipine suppresses the pressor response induced by sympathetic nerve stimulation and angiotensin II in pithed rats. Cilnidipine or omega-conotoxin MVIIA decreases mean blood pressure, but slightly increases heart rate in anesthetized rats. Cilnidipine can affect sympathetic N-type Ca(2+) channels in addition to vascular L-type Ca(2+) channels in antihypertensive doses in the rat in vivo. |
-  Takahara A, et al. Hypertens Res,?003, 26(9), 743-747.
-  Sakamoto K, et al. Exp Eye Res,?009, 88(5), 974-982.
-  Fan YY, et al. J Hypertens,?010, 28(5), 1034-1043.
|In vitro||DMSO||99 mg/mL (201.0 mM)|
|Ethanol||15 mg/mL (30.45 mM)|
|In vivo||Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02343250||Completed||Hypertension||IlDong Pharmaceutical Co Ltd||March 2015||Phase 1|
|NCT02145104||Unknown status||Hypertension||IlDong Pharmaceutical Co Ltd||May 2014||Phase 3|
|NCT00890279||Unknown status||Kidney, Polycystic, Autosomal Dominant||Ministry of Health, Labour and Welfare, Japan||July 2009||Phase 2|
|NCT00541853||Unknown status||Kidney, Polycystic, Autosomal Dominant||Kyorin University|Ministry of Health, Labour and Welfare, Japan||December 2007||Phase 4|
|NCT00325936||Completed||Hypertension|Metabolic Syndrome X||Boryung Pharmaceutical Co., Ltd||July 2005||Phase 4|
|NCT00325637||Completed||Hypertension|Stroke||Boryung Pharmaceutical Co., Ltd||January 2005||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.